Incidents of AF were observed less with newer generations of BTKis, namely, acalabrutinib [19] or zanbrutinib, when compared with ibrutinib among patients with B-cell malignancies [20,21], which have a greater selectivity for the BTK enzyme [18]. This evidence concerns the gene BTK and atrial fibrillation.